Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

6(60.0%)

Phase 1

3(30.0%)

N/A

1(10.0%)

10Total

Phase 2(6)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT04742907Phase 2Completed

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

Role: lead

NCT02232893Phase 2Completed

Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy

Role: lead

NCT02074579Phase 2Completed

A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

Role: lead

NCT01890837Phase 1Completed

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

Role: lead

NCT01388933Phase 2Terminated

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Role: lead

NCT01348152Phase 2Completed

Effect of TU-100 in Patients With Functional Constipation

Role: lead

NCT00266461Phase 2Completed

A Tolerability and Efficacy Study of TU-100 For The Treatment of Postoperative Ileus

Role: lead

NCT00871325Phase 1Completed

Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans

Role: lead

NCT01139216Phase 1Completed

Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation

Role: lead

NCT00522093Not ApplicableCompleted

Efficacy and Safety of TJ-100 in the Treatment of Chronic Constipation

Role: collaborator

All 10 trials loaded